CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.66 USD 3.91% Market Closed
Market Cap: 596.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CureVac NV
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Common Shares Outstanding
€224m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Common Shares Outstanding
€237.7m
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Common Shares Outstanding
€37.7m
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
4%
Immatics NV
NASDAQ:IMTX
Common Shares Outstanding
€84.7m
CAGR 3-Years
10%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Common Shares Outstanding
€39.6m
CAGR 3-Years
26%
CAGR 5-Years
0%
CAGR 10-Years
0%
Formycon AG
XETRA:FYB
Common Shares Outstanding
€16.1m
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
596.7m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
5.16 USD
Undervaluation 48%
Intrinsic Value
Price

See Also

What is CureVac NV's Common Shares Outstanding?
Common Shares Outstanding
224m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Common Shares Outstanding amounts to 224m EUR.

What is CureVac NV's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
5%

Over the last year, the Common Shares Outstanding growth was 15%. The average annual Common Shares Outstanding growth rates for CureVac NV have been 7% over the past three years , 5% over the past five years .

Back to Top